Navigation Links
Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
Date:5/27/2009

BUFFALO, N.Y., May 27 /PRNewswire/ -- Kinex Pharmaceuticals will present results from a Phase 1 clinical study with KX2-391, at the ASCO 2009 Annual Meeting in Orlando, on May 29, 2009. The study was carried out at MD Anderson, Roswell Park Cancer Institute (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, the Principal Investigator from RPCI will deliver the presentation entitled "Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies."

The presentation will provide data from this multi-center Phase 1 trial that utilized the standard 3+3 design to determine the Maximum Tolerated Dose (MTD), safety, and pharmacokinetics (PK) of KX2-391 in patients with refractory solid tumors. Patients who responded to treatment will be highlighted.

This presentation was designated as Best of ASCO(R) which features high-impact abstracts from the 2009 ASCO Annual Meeting that represent the most relevant, cutting-edge science in oncology today. This information has been selected to be presented at meetings in the US and internationally because it highlights the latest scientific findings in primary disease sites and practice-changing advances in cancer prevention and treatment.

Kinex Pharmaceuticals is a drug discovery and development company that is focused on next generation drugs to treat cancer and immuno-inflammatory diseases. The Company has utilized its platform technologies to identify highly selective inhibitors of therapeutically relevant targets that are involved in signal transduction and cell cycle control.

CONTACT: Lyn Dyster, Vice President, Research Operations of Kinex Pharmaceuticals, +1-716-881-8984


'/>"/>
SOURCE Kinex Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 ... "US Market Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices ... ... The full report suite on the ... fluid external drainage systems, intracranial pressure monitoring devices, detachable coils, ...
(Date:11/30/2016)... Nov. 30, 2016 Varian Medical Systems (NYSE: ... America,s Most JUST Company in the Healthcare Equipment and ... magazine,s inaugural "JUST 100 List." The rankings are ... surveys ever conducted on attitudes towards corporate behavior, involving ... list ranks U.S companies against their peers within 32 ...
Breaking Medicine Technology:
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 ... ... over 5,100 hot meals to needy individuals and families from eight different sites ... Florida on Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ‘Tis the ... winners of $1,000 each from the National Family Partnership and the Drug Enforcement Administration ... who decorated their homes and the 10 winning schools who decorated their campuses with ...
(Date:11/30/2016)... ... ... "I hate when the mixture of saliva and toothpaste runs down my toothbrush ... N.J. "I thought that there had to be a way to prevent this mess, ... to prevent saliva and toothpaste from running down the brush handle onto the hand ...
(Date:11/30/2016)... CA (PRWEB) , ... November 30, 2016 , ... ... disorder and mental health treatment has announced the opening of a new residential ... treatment for girls with mental health issues such as severe anxiety, depression, bi-polar ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... community that the FDA Binding Guidance goes into effect next month. Sponsors whose ... in the FDA Data Standards Catalog. The current FDA Data Standards Catalog specifies ...
Breaking Medicine News(10 mins):